Join
Live feed
·
PRReleasevia Quantisnow
CervoMed Inc. logo

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

ByQuantisnow·Wall Street's wire, on your screen.
CRVO· CervoMed Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRVO (CervoMed Inc.) and more on Quantisnow.